Drug Candidate Marketplace

Drug Candidate Marketplace lists the information of drug candidates, therapeutic targets and drug discovery technologies. Visitors can use search functions based on the interests and needs. If you have a drug candidates, therapeutic targets and drug discovery technologies that you are interested in and would like to gain more information, please contact us by clicking the inquiry button. After consenting to the terms of condition and use of our services, the requested information will be provided to you.

Date Candidate Mechanism of action Indication Route Development stage Note
09/20/18 GEM045 Autotaxin Inhibitor NASH Oral Discovery~ Preclinical Showed significant effects in both MCD (NASH) and chronic pancreatitis models.
Lead optimizations ongoing.
09/20/18 GEM044 TLR4 antagonist and NOX1/4 inhibitor NASH, AIH, IPF and IBD Oral Discovery~ Preclinical 5-10 times more potent on NOX activity than GKT-831.
Hepatoprotection in AIH in mice.
Showed antifibrotic efficacy in caerulein-induced pancreatic fibrosis in mice.
Lead optimization for improved PK and safety ongoing.
09/20/18 GEM043 TLR4 antagonist NASH Oral Phase 2 Not demonstrated statistically significant improvement in fatty liver, liver enzymes, and metabolic biomarkers. Contact
09/20/18 GEM042 TLR4 antagonist CLD, NAFLD, AIH and CD Oral Phase 2 CLD(chronic liver disease by HCV infection): A strong trend of improvement of liver function and safety in Phase 2.
NAFLD: nonalcoholic fatty liver disease, the phase2 data is pending final analysis.
AIH: autoimmune hepatitis (orphan designation), the phase2 data is pending final analysis.
CD(Crohn's disease):good efficacy in three Phase 2 pilot studies
09/20/18 GEM041 Dual inhibitor of catechol-O-methyltransferase and dopa decarboxylase Parkinson's disease Oral Preclinical First dual inhibitor in the World.
Almost same inhibitory activities for the two enzymes.
The enzyme activities were inhibited strongly in the liver, but not in the brain.
08/31/18 GEM040 Topical anti-inflammatory Joint pain, Muscle pain, Gout, Local inflammatory pain see Note Preclinical Topical formulations of Ibuprofen, Naproxen, Diclofenac to use in the treatment of inflamatory pain and related conditions
Formulation shows 5 to 10X increase human skin permeation coupled
Potential for OTC or RX introduction: minimal development timeline

08/31/18 GEM039 Antifungal Onychomycosis see Note Preclinical Novel and unique topical formulation of Terbenafine with exceptional permeation (40 fold) across the human nail.
Potential for OTC or RX introduction: minimal development timeline

08/31/18 GEM038 Locally acting anti-inflammatory- Trigeminal neuro-inflammation Migraine Phase 2a Clinical POC in acute migraine therapy in Phase 2a
Efficacy comparable to Triptans but with no systemic side effects or restrictions
Shortened development timelines (NDA:2021)
Product opportunity for use in Temporomandibular Joint Disease and trigeminal neuralgias
08/31/18 GEM037 Allosteric modulator of the CCR3 receptor Asthma, rhinitis Oral Phase 2a In phase 2a:
Highly significant effects on the methacholine provocative response
Showed trends to improvement in EAR (Early Phase Allergic Response)
Reduced induced sputum eosinophil percentage and increased percent blood eosinophil
08/27/18 GEM036 Hematopoietic stem cell fucosylation Prevention of infection & GvHD from hematopoietic stem cell transplantation see Note Phase 3 ready with FDA SPA In Phase II study:
Statistically significant acceleration of immune system reconstitution
(neutrophil/platelet recovery)
Significantly reduced infection and GvHD
Improved survival
Positioned to be best-in-classNo
reports of adverse event specifically attributable to fucosylation